YD Bio director exercises 5,749 RSUs and receives grant
YD Bio Ltd director Chang Kochi reported equity compensation activity involving Restricted Share Units (RSUs) and ordinary shares.
Rhea-AI Filing Summary
YD Bio Ltd director Chang Kochi reported equity compensation activity involving Restricted Share Units (RSUs) and ordinary shares. On June 30, 2026, Kochi exercised 5,749 RSUs into the same number of ordinary shares at a stated price of $0.0000 per share, increasing direct holdings to 7,830 ordinary shares.
On the same date, Kochi also received a new grant of 5,749 RSUs with each RSU representing one ordinary share of YD Bio Ltd. According to the equity plan, the RSUs relate to a target aggregate grant date fair value of $60,000, vesting in four equal quarterly installments determined using a seven trading-day volume-weighted average price.
Positive
- None.
Negative
- None.
Insider Trade Summary
5,749 shares exercised/converted
Exercise
3 txns
Insider
Chang Kochi
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Share Units | 5,749 | $0.00 | $0.00 |
| Exercise | Restricted Share Units | 5,749 | $0.00 | $0.00 |
| Exercise | Ordinary Shares | 5,749 | $0.00 | $0.00 |
Holdings After Transaction:
Restricted Share Units — 0 contracts (Direct);
Ordinary Shares — 7,830 shares (Direct)
Footnotes (3)
- F1. Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share, par value $0.0001 per share ("Ordinary Shares"), of YD Bio Limited.
- F2. The RSUs were granted pursuant to the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000 on March 31, 2026 (the "Granted RSUs"). The Granted RSUs vest in four equal quarterly installments beginning March 31, 2026, with the number of RSUs subject to vesting to be determined on the applicable vesting date by dividing $15,000 by the seven (7) trading-day volume-weighted average price of the Company's Ordinary Shares ending on the trading day immediately prior to such vesting.
- F3. The Reporting Person became entitled to a fixed number of RSUs on June 30, 2026 (the "Vesting Date").
Key Figures
RSUs exercised: 5,749 RSUs / 5,749 shares
Ordinary shares held: 7,830 shares
New RSU grant size: 5,749 RSUs
+3 more
6 metrics
RSUs exercised
5,749 RSUs / 5,749 shares
Exercise into ordinary shares on June 30, 2026
Ordinary shares held
7,830 shares
Direct holdings after June 30, 2026 transactions
New RSU grant size
5,749 RSUs
Grant reported with transaction code A on June 30, 2026
Target grant value
$60,000
Aggregate target grant date fair value on March 31, 2026
Quarterly vesting tranche
$15,000 per tranche
Each of four quarterly installments under equity plan
VWAP basis
7 trading days
Volume‑weighted average price period for RSU share calculation
Key Terms
Restricted Share Units, Equity Incentive Plan, volume-weighted average price
3 terms
Equity Incentive Plan financial
"The RSUs were granted pursuant to the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
volume-weighted average price financial
"by dividing $15,000 by the seven (7) trading-day volume-weighted average price of the Company's Ordinary Shares"
Volume-weighted average price (VWAP) is the average price of a stock over a specific time period where each trade is weighted by the number of shares traded, so larger trades influence the average more than small ones. Investors and traders use VWAP as a reference point to judge whether trades are happening at relatively good or poor prices—like checking the average price paid for an item at a market where bulk purchases count more than single-item buys.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did YD Bio (YDES) director Chang Kochi report?
Chang Kochi exercised 5,749 Restricted Share Units into 5,749 ordinary shares and received a new grant of 5,749 RSUs. These transactions are equity compensation events, not open‑market share purchases or sales.
What are the terms of Chang Kochi’s new RSU grant at YD Bio (YDES)?
The new RSUs have an aggregate target grant date fair value of $60,000, granted on March 31, 2026. They vest in four equal quarterly installments, each calculated by dividing $15,000 by a seven trading‑day volume‑weighted average price of YD Bio’s ordinary shares.
Does the YD Bio Form 4 show any open‑market buying or selling by Chang Kochi?
The Form 4 does not show open‑market buying or selling. All reported transactions are coded as derivative exercises (M) and a grant (A), reflecting equity compensation activity rather than discretionary market trades in YD Bio’s ordinary shares.
What does each YD Bio RSU reported for Chang Kochi represent?
Each Restricted Share Unit represents a contingent right to receive one ordinary share of YD Bio Ltd. Delivery of shares depends on vesting conditions specified in the equity incentive plan and reaching the applicable vesting dates described in the Form 4 footnotes.
AI-generated analysis. How Rhea-AI works. Not financial advice.
